Decoding the Intronic Signature of Cancer

IDSC Fellows

Dec. 3. 2025



Decoding the Intronic Signature of Cancer

Linking intron subtypes, splicing dysregulation, and tumor biology

Only ~1-2% of the human genome encodes proteins

~78.5% of the human genome is transcribed non-coding regions, including introns.

Because most transcribed sequences are non-coding, these regions play major regulatory roles in transcription and RNA processing.

Disruptions in the non-coding genome are increasingly recognized as a **major drivers of human disease**, including **cancer**.

(ENCODE-based estimate) 1.5 % 20 % **78.5 % Genomic Category** Non-transcribed Protein-coding exons Transcribed non-coding ¹ Evans et al., 2016


Human Genome Composition

How do different intron subtypes shape mutation burden, splicing sensitivity, and pathway-level vulnerabilities in cancer genomes?

What Are Introns?



Non-coding sequences within genes, removed during RNA processing






Research Overview

Integrating intron subtypes with pan-cancer mutations

- Annotate refined intron subtypes across TCGA + POC matched tumor/normal
- 2. Identify subtype-enriched mutations:
 - Splice-site disruptions
 - Branchpoint mutation
 - Loss of Function variants / NMD-triggering variants
 - Enrichment analysis vs. background mutation rate
- 3. Connect intron subtypes to oncogenic pathways
- 4. Quantify subtype-specific splicing sensitivity


Computational Challenges

- Severe Intron Class imbalance
- Massive scale integration: millions of mutations × intron subtypes
- Subtype sensitivity detection under noisy cancer genomes
- Extracting real signals from mutational background
- Linking mutation → subtype → pathway in a unified model





Preliminary Result: Non-Canonical Introns Reveal Unresolved Structure



Suggests ambiguous boundaries within major/minor groups

→ Requires high-resolution modeling with larger datasets + advanced sequence models.



What This Research Enables



Reveal hidden intron subtype structure



Detect aberrant splicing events with high sensitivity



Uncover novel isoforms uniquely captured by long-read sequencing



Identify subtypespecific splicing vulnerabilities in cancer

Ultimately, my goal is to bridge the gap between large-scale genomic data and biological understanding by using computational tools to reveal hidden patterns, vulnerabilities, and novel isoforms within the non-coding genome.